Last reviewed · How we verify
Candesartan treated group
At a glance
| Generic name | Candesartan treated group |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- Improved Treatment and Monitoring of Alzheimer's Disease (PHASE2)
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- Precision Treatment With Angiotensin Converting Enzyme Inhibitor (PHASE4)
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan treated group CI brief — competitive landscape report
- Candesartan treated group updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI